Search Page

1

Cite

Share

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Casanovas O, et al. Cancer Cell. 2005 Oct;8(4):299-309. doi: 10.1016/j.ccr.2005.09.005. Cancer Cell. 2005. PMID: 16226705

Cite

Share

2

Cite

Share

Relevance of angiogenesis in neuroendocrine tumors.

Teulé A, Casanovas O. Teulé A, et al. Among authors: casanovas o. Target Oncol. 2012 Jun;7(2):93-8. doi: 10.1007/s11523-012-0217-x. Epub 2012 May 17. Target Oncol. 2012. PMID: 22592949 Review.

Cite

Share

3

Cite

Share

Angiogenesis and Metabolism: Entwined for Therapy Resistance.

Jiménez-Valerio G, Casanovas O. Jiménez-Valerio G, et al. Among authors: casanovas o. Trends Cancer. 2017 Jan;3(1):10-18. doi: 10.1016/j.trecan.2016.11.007. Epub 2016 Dec 26. Trends Cancer. 2017. PMID: 28718423 Review.

Cite

Share

4

Cite

Share

The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels.

Alsina-Sanchis E, Figueras A, Lahiguera Á, Vidal A, Casanovas O, Graupera M, Villanueva A, Viñals F. Alsina-Sanchis E, et al. Among authors: casanovas o. Int J Cancer. 2016 Oct 15;139(8):1894-903. doi: 10.1002/ijc.30233. Epub 2016 Jun 25. Int J Cancer. 2016. PMID: 27299695

Cite

Share

5

Cite

Share

Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors.

Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A, Milà-Guasch M, Viñals F, Baselga J, Casanovas O, Graupera M. Soler A, et al. Among authors: casanovas o. Clin Cancer Res. 2016 Dec 1;22(23):5805-5817. doi: 10.1158/1078-0432.CCR-15-3051. Epub 2016 May 25. Clin Cancer Res. 2016. PMID: 27225693 Free PMC article.

Cite

Share

6

Cite

Share

Antiangiogenic therapies: going beyond their limits.

Moserle L, Jiménez-Valerio G, Casanovas O. Moserle L, et al. Among authors: casanovas o. Cancer Discov. 2014 Jan;4(1):31-41. doi: 10.1158/2159-8290.CD-13-0199. Epub 2013 Dec 19. Cancer Discov. 2014. PMID: 24356098 Review.

Cite

Share

7

Cite

Share

The adaptive stroma joining the antiangiogenic resistance front.

Casanovas O. Casanovas O. J Clin Invest. 2011 Apr;121(4):1244-7. doi: 10.1172/JCI46430. Epub 2011 Mar 23. J Clin Invest. 2011. PMID: 21436579 Free PMC article.

Cite

Share

8

Cite

Share

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F. Castillo-Avila W, et al. Among authors: casanovas o. Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417025

Cite

Share

9

Cite

Share

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Pàez-Ribes M, et al. Among authors: casanovas o. Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027. Cancer Cell. 2009. PMID: 19249680 Free PMC article.

Cite

Share

10

Cite

Share

Use of a mouse model of pancreatic neuroendocrine tumors to find pericyte biomarkers of resistance to anti-angiogenic therapy.

Franco M, Pàez-Ribes M, Cortez E, Casanovas O, Pietras K. Franco M, et al. Among authors: casanovas o. Horm Metab Res. 2011 Nov;43(12):884-9. doi: 10.1055/s-0031-1284381. Epub 2011 Sep 29. Horm Metab Res. 2011. PMID: 21960459

Cite

Share